ArticleEndocrine2026
Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo prospectively evaluate audiologic outcomes in patients with thyroid eye disease (TED) treated with teprotumumab, focusing on longitudinal changes in hearing sensitivity and cochlear function.
methodsAdult patients initiating teprotumumab therapy at a tertiary care center (2023-2025) underwent audiologic evaluations before, during, and after treatment. Pure-tone audiometry (500-12,500 Hz) and distortion product otoacoustic emissions (DPOAEs; 842-7996 Hz) were analyzed using three-level mixed-effects models to assess longitudinal changes, with secondary analyses controlling for baseline hearing loss.
resultsSixteen participants completed the study. Significant threshold elevations suggesting reduced hearing sensitivity were observed in 6 of 9 audiometric frequencies (p < 0.05), most prominent during active therapy. Partial recovery occurred post-treatment, though thresholds rarely returned to baseline. DPOAE analyses showed fewer consistent changes, with significant amplitude reductions at only 4 of 24 frequencies. Adjusting for baseline hearing loss reduced significance for isolated measures but not overall trends. As multiple comparisons were not formally adjusted for, these findings should be interpreted as exploratory and hypothesis-generating.
conclusionsTeprotumumab therapy appears to be associated with sensorineural hearing decline detected by audiometry but incompletely captured by DPOAEs. This mismatch suggests injury beyond outer hair cells, possibly involving inner hair cells or neural elements. These findings may support audiometric monitoring during treatment and further research into teprotumumab's ototoxic mechanisms during treatment of TED.
Indexed as
Identifiers
42455407What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.